Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 3Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 94Gastrointestinal 8Thoracic 6Sarcoma 6Lymphoid 6Head & Neck 4Gynecologic 4Genitourinary 4Other solid neoplasm 3Other hematologic neoplasm 3CNS 3Dermatologic 2Plasma cell 1Other neoplasm 1Myeloid 1

Conditions

Melanoma 2Testicular Neoplasms 1Teratoma 1Rectal Neoplasms 1Neoplasms 1Colonic Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Ipilimumab 123pembrolizumab 101Nivolumab 100aldesleukin 89Cyclophosphamide 85fludarabine phosphate 64Interleukin-2 58Dacarbazine 573-ingenyl angelate 42Vemurafenib 39Temozolomide 39Imiquimod 39trametinib 37sargramostim 37Peripheral Blood Stem Cell Transplantation 36incomplete Freund's adjuvant 35dabrafenib 32fludarabine 31Radiotherapy 31Aminolevulinic Acid 30Bevacizumab 29Carboplatin 28Whole-Body Irradiation 25Photochemotherapy 25Paclitaxel 25Filgrastim 25Biopsy 25Interferon-alpha 24Cisplatin 23Sorafenib 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × palbociclib × Dermatologic × Clear all
NCT01037790 2021-03-11

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

Abramson Cancer Center at Penn Medicine

Phase 2 Completed
304 enrolled 12 charts
BreastDermatologicGastrointestinalGenitourinary

Breast Neoplasms, Colonic Neoplasms, Melanoma, Rectal Neoplasms, Teratoma, Testicular Neoplasms, Breast Neoplasms, Male

NCT02065063 2018-06-01

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors

GlaxoSmithKline

Phase 1 Completed
28 enrolled
Dermatologic

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡